• The Lancet Oncology in conversation with

  • 著者： The Lancet Group
  • ポッドキャスト

The Lancet Oncology in conversation with

著者： The Lancet Group
無料で聴く

  • サマリー

  • Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

    A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.
    © 2024 The Lancet Group
    続きを読む 一部表示
activate_samplebutton_t1
エピソード
  • Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

    Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)
    2024/08/27

    Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    13 分
  • Emmy Boerrigter on dose selection of novel anticancer drugs

    Emmy Boerrigter on dose selection of novel anticancer drugs
    2024/07/29

    Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.

    Read the full article:
    https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00134-7?dgcid=buzzsprout_icw_podcast_generic_lanonc

    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    12 分
  • Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations

    Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations
    2024/06/24

    Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints.

    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    37 分

あらすじ・解説

Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.
© 2024 The Lancet Group
身体的病い・疾患 衛生・健康的な生活 生物科学
続きを読む 一部表示

The Lancet Oncology in conversation withに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。